Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia

New England Journal of Medicine

Volumn 350, Issue 16, 2004, Pages 1617-1628

  Valk, Peter J M ^a   Verhaak, Roel G W ^a   Beijen, M Antoinette ^a   Erpelinck, Claudia A J ^a   Van Waalwijk Van Doorn Khosrovani, Sahar Barjesteh ^a   Boer, Judith M ^b   Beverloo, H Berna ^a   Moorhouse, Michael J ^a   Van Der Spek, Peter J ^a   Löwenberg, Bob ^a   Delwel, Ruud ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; BONE MARROW; CANCER CLASSIFICATION; CANCER SURVIVAL; CEBPA GENE; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 8; CLUSTER ANALYSIS; CONTROLLED STUDY; DEVICE; DNA MICROARRAY; EXPRESSED SEQUENCE TAG; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; ONCOGENE; ONCOGENE EVI1; ONCOGENE RAS; PREDICTION ANALYSIS OF MICROARRAY; PRIORITY JOURNAL; PROGNOSIS; SIGNIFICANCE ANALYSIS OF MICROARRAY; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ALGORITHMS; CHROMOSOME ABERRATIONS; CLUSTER ANALYSIS; CYTOGENETIC ANALYSIS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SOFTWARE; SURVIVAL ANALYSIS;

EID: 11144358111     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa040465     Document Type: Article

References (29)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62. [Erratum, N Engl J Med 1999;341:1484.]
2. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62. [Erratum, N Engl J Med 1999;341:1484.]
3. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000;96:4075-83.
4. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36.
5. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998;92:2322-33.
6. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-20.
7. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-ras gene mutations in acute myeloid leukemia. Blood 1999;93:3074-80.
8. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-42.
9. Barjesteh van Waalwijk S, Erpelinck C, van Putten WL, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003;101:837-45.
10. van Waalwijk van Doom-Khosrovani SB, Erpelinck C, Meijer J, et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 2003;4:31-40.
11. Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002;100:2717-23.
12. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002;30:41-7.
13. Debemardi S, Lillington DM, Chaplin T, et al. Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. Genes Chromosomes Cancer 2003;37:149-58.
14. Schoch C, Kohlmann A, Schnittger S, et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci U S A 2002;99:10008-13.
15. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
16. Lowenberg B, Boogaerts MA, Daenen SM, et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997;15:3496-506.
17. Löwenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349:743-52.
18. Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. Blood (in press).
19. Chomczynsld P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
20. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21. [Erratum, Proc Natl Acad Sci U S A 2001;98:10515.]
21. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21. [Erratum, Proc Natl Acad Sci U S A 2001;98:10515.]
22. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567-72.
23. Valk PJM, Bowen DT, Frew ME, Goodeve AC, Löwenberg B, Reilly JT. Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukaemia and inv(16). Haematologica 2004;89:106.
24. Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 2003;121:775-7.
25. Lo Coco F, De Rossi G, Pasqualetti D, et al. CD7 positive acute myeloid leukaemia: a subtype associated with cell immaturity. Br J Haematol 1989;73:480-5.
26. Boeckx N, Willemse MJ, Szczepanski T, et al. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia. Leukemia 2002;16:368-75.
27. Touw I, Donath J, Pouwels K, et al. Acute myeloid leukemias with chromosomal abnormalities involving the 21q22 region identified by their in vitro responsiveness to interleukin-5. Leukemia 1991;5:687-92.
28. Kim HP, Kelly J, Leonard WJ. The basis for IL-2-induced IL-2 receptor alpha chain gene regulation: importance of two widely separated IL-2 response elements. Immunity 2001;15:159-72.
29. Lilly M, Le T, Holland P, Hendrickson SL. Sustained expression of the pim-1 kinase is specifically induced in myeloid cells by cytokines whose receptors are structurally related. Oncogene 1992;7:727-32.